|

obicetrapib 10 mg + ezetimibe 10 mg FDC daily Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: FDC

Pipeline

Phase 3: 2

Top Sponsors

  • NewAmsterdam Pharma2

Indications

  • Lipidemia2
  • Plaque, Atherosclerotic1
  • Metabolic Syndrome (MetS)1
  • Type 2 Diabetes (T2DM)1
  • Heart Disease1

Sun City West, Arizona1 trial

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Clinical Research Institute of Arizona

Phase 3

Hialeah, Florida1 trial

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

NGMR

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.